Geftinat 250 Mg Tablet

Product Description

Geftinat 250 Mg Tablet contains the active ingredient gefitinib and is usually prescribed when other treatments have failed or when the cancer has spread. It is a medication used in the treatment of non-small cell lung cancer (NSCLC) that has certain genetic mutations, such as mutations in the epidermal growth factor receptor (EGFR) gene. Gefitinib is a tyrosine kinase inhibitor that works by inhibiting the activity of the EGFR protein, which is involved in the growth and spread of cancer cells. Geftinat 250 Mg Tablet is effective in the treatment of NSCLC with certain EGFR mutations, leading to improvements in progression-free survival and overall survival in some patients.

Specification